替米沙坦对糖尿病肾病大鼠肾脏α-SMA表达影响的实验研究  

Renal expression of α-SMA in diabetic nephropathy and the protective effects of Telmisartan

作　　者：易春霞[1] 廖海强[1] 周于禄[1] 裴奇[1] 刘世坤[1] 

机构地区：[1]中南大学湘雅三医院药剂科,长沙410013

出　　处：《中南药学》2006年第4期259-262,共4页Central South Pharmacy

摘　　要：目的探讨糖尿病肾病肾脏α-平滑肌肌动蛋白(-αSMA)的表达及血管紧张素-Ⅱ受体1拮抗剂替米沙坦对其表达的影响。方法将28只SD大鼠单次腹腔注射STZ(60 mg.kg-1)诱发实验性糖尿病肾病,随机分为糖尿病肾病组(D)和替米沙坦组(T),14只.组-1,另将14只鼠龄及体重相等的SD大鼠作为正常对照组。药物干预12周后,称量体重,收集24 h尿液及血标本,取大鼠肾脏组织行免疫组织化学检查-αSMA。结果与正常组相比,糖尿病肾病大鼠肾小球内-αSMA蛋白表达、24 h尿蛋白排泄量以及肾功能各项指标大幅度增高(P<0.01)且成相关关系,替米沙坦能显著性抑制-αSMA蛋白表达,减少尿蛋白排泄量以及降低肾功能各项指标(P<0.01),并能降低DN大鼠血糖浓度。结论糖尿病肾病大鼠肾脏损伤可能与-αSMA表达增高有关,替米沙坦下调-αSMA表达,减少尿蛋白排泄以及降低肾功能指标,可能是其肾脏保护作用机制之一。OBJECTIVE To observe the renal expression of α-smooth muscle actin （α-SMA） in diabetic nephropathy （DN） rats and the effects of telmisartan as angiotersin Ⅱ type 1 （AT1） receptor antagonist. METHODS Twenty-eight diabetic nephropathy Sprague-Dawley （SD） rats induced with intraperitoneal injection of streptozotocin （STZ） were randomly divided into two groups： DN rats without therapy （group D, n=14） and DN rats treated with telmisartan （group T, n=14）. Fourteen SD rats were used as the control （group N）. The urine at 24 h and blood samples were collected after the treatment with telmisartan for 12 wks. The rats were killed and the α-SMA was determined with immunohistochemistry. RESULTS Expression of α-SMA in the nephridial tissue , the concentration of urine protein （UPro） at 24 h , and the renal function indicatrix （BUN, Ccr, ＇and UA） were significantly higher than those in group N （P〈0.01）. The expression of α-SMA and UPro. BUN, Ccr, UA, and BG decreased significantly after the treatment with telmisartan （P〈0. 01） . CONCLUSIONS The expression of α-SMA and UPro were increased significantly in the DN rats. Telmisartan has significant renal protective effects on DN rats, and inhibition of α-SMA activation may be one of the potential mechanisms.

关 键 词：Α-SMA 糖尿病肾病 替米沙坦 

分 类 号：R965[医药卫生—药理学]